We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+14.17%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$883M
AUM Growth
+$301M
Cap. Flow
+$204M
Cap. Flow %
23.13%
Top 10 Hldgs %
65.86%
Holding
75
New
21
Increased
22
Reduced
4
Closed
17

Top Buys

Rank Stock Value
1
ITRM
Iterum Therapeutics
ITRM
+$20.8M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$16.7M
3
AGN
Allergan plc
AGN
+$16.4M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$15.4M
5
CELG
Celgene Corp
CELG
+$15.3M

Top Sells

Rank Stock Value
1
NCNA
NuCana
NCNA
+$98.5M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$16.5M
3
APLS
Apellis Pharmaceuticals
APLS
+$6.8M
4
ATYR
aTyr Pharma
ATYR
+$4.95M
5
BMY icon
Bristol-Myers Squibb
BMY
+$951K

Sector Composition

Rank Sector Weight
1 Healthcare 81.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.66B
$6.4M 0.72%
+48,400
New +$4.56M
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.06M 0.69%
1,769,583
+1,582,809
+847% +$6.18M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$5.92M 0.67%
+151,161
New +$7.64M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$5.85M 0.66%
+92,200
New +$7.34M
SYBX
30
DELISTED
Synlogic
SYBX
$5.65M 0.64%
38,331
– –
OCGN icon
31
Ocugen
OCGN
$410M
$5.19M 0.59%
34,617
– –
CLSD
32
DELISTED
Clearside Biomedical
CLSD
$4.63M 0.52%
28,860
+26,501
+1,123% +$4.47M
CPRX
33
DELISTED
Catalyst Pharmaceutical
CPRX
$4.52M 0.51%
1,449,957
+1,301,902
+879% +$3.95M
RYTM icon
34
Rhythm Pharmaceuticals
RYTM
$7B
$4.39M 0.5%
+140,300
New +$3.84M
PTCT icon
35
PTC Therapeutics
PTCT
$6.37B
$4.29M 0.49%
127,079
+101,350
+394% +$3.16M
KALA icon
36
KALA BIO
KALA
$11.8M
$4.17M 0.47%
121
+113
+1,413% +$4.34M
OTIC
37
DELISTED
Otonomy, Inc.
OTIC
$3.77M 0.43%
979,978
+881,354
+894% +$3.67M
HSTO
38
DELISTED
Histogen Inc. Common Stock
HSTO
$3.68M 0.42%
+4,294
New +$3.57M
PBYI icon
39
Puma Biotechnology
PBYI
$406M
$3.66M 0.42%
+61,936
New +$3.59M
SPPI
40
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$3.56M 0.4%
+169,965
New +$3.15M
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.42M 0.39%
682,399
+610,382
+848% +$3.14M
DERM
42
DELISTED
Dermira, Inc.
DERM
$3.35M 0.38%
364,340
+316,020
+654% +$2.95M
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.14M 0.36%
89,909
+60,526
+206% +$1.84M
KURA icon
44
Kura Oncology
KURA
$922M
$3.06M 0.35%
+167,900
New +$2.84M
PDSB icon
45
PDS Biotechnology
PDSB
$38.1M
$2.94M 0.33%
142,636
– –
SVRA icon
46
Savara
SVRA
$1.13B
$2.9M 0.33%
+256,692
New +$2.58M
AMAG
47
DELISTED
AMAG Pharmaceuticals
AMAG
$2.78M 0.31%
+142,511
New +$3.15M
CHMA
48
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.44M 0.28%
1,767,102
+136,881
+8% +$207K
KDNY
49
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.69M 0.19%
48,264
+44,925
+1,345% +$1.72M
CALA
50
DELISTED
Calithera Biosciences, Inc
CALA
$1.49M 0.17%
14,861
+13,865
+1,392% +$1.57M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Sofinnova Investments held 75 positions worth $883M, up 52% from $582M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments deployed $204M of net new capital in Q2 2018, opening 21 new positions and adding to 22 existing holdings. Its largest new stake was Iterum Therapeutics: 115,101 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was NuCana, an estimated $98.5M trimmed.

  • Sofinnova Investments's largest Q2 2018 buy was Iterum Therapeutics: 115,101 shares worth $18.8M.
  • Sofinnova Investments added most to Allergan plc in Q2 2018, an estimated $16.4M increase.
  • Sofinnova Investments's biggest Q2 2018 reduction was NuCana, cutting an estimated $98.5M.
  • Sofinnova Investments fully exited aTyr Pharma in Q2 2018, selling an estimated $4.95M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $883M portfolio in Q2 2018.
  • Sofinnova Investments opened 21 new positions and closed 17 in Q2 2018.
  • Sofinnova Investments's portfolio value rose 52% quarter-over-quarter to $883M.

Based on Sofinnova Investments's 13F filing for Q2 2018, filed 14 Aug 2018.